pyrimethamine has been researched along with Triple Negative Breast Neoplasms in 1 studies
Maloprim: contains above 2 cpds
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, B | 1 |
| Fathi, S | 1 |
| Mortley, S | 1 |
| Mohiuddin, M | 1 |
| Jang, YC | 1 |
| Oyelere, AK | 1 |
1 other study available for pyrimethamine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Chlorocebus aethiops; Dose-Resp | 2020 |